SCHEDULE: Deep Track Capital Discloses 7% Stake in Aclaris Therapeutics

Deep Track Capital and its affiliates have reported a 7.0% beneficial ownership stake in Aclaris Therapeutics, Inc., totaling 9,345,000 shares.

Summary

• Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin collectively beneficially own 9,345,000 shares of Aclaris Therapeutics, Inc. common stock.
• This ownership represents 7.0% of the company's outstanding common stock.
• The percentage of class is calculated based on 133,295,189 shares, which includes 120,595,189 common shares outstanding as of January 30, 2026, and an additional 12.7 million shares sold between March 2, 2026, and March 9, 2026.
• The reporting persons share both voting and dispositive power over all 9,345,000 beneficially owned shares.
• The securities were acquired for investment purposes and not with the intent to change or influence control of Aclaris Therapeutics.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as moderately positive, as a significant stake by a specialized investment firm can indicate confidence in the company's prospects, though it doesn't provide new operational or financial data.

Positives

• A significant 7.0% beneficial ownership stake by Deep Track Capital, a specialized biotechnology investor, may signal confidence in Aclaris Therapeutics' future prospects and strategic direction.

Negatives

• No direct negative information regarding Aclaris Therapeutics' operational or financial performance is presented in this beneficial ownership report.

Industry Context

StockSavvy.ai notes that a significant stake by a specialized biotechnology investor like Deep Track Capital often signals a belief in the long-term potential of Aclaris Therapeutics' pipeline or strategic direction within the competitive biotechnology sector.

Stakeholder Impact

• Shareholders may view the entry of a significant institutional investor as a positive signal, potentially increasing confidence in the company's valuation and future prospects.
• The increased institutional ownership could lead to greater scrutiny of management decisions and corporate strategy.

Key Dates

Recommendation

The disclosure of a 7.0% beneficial ownership by Deep Track Capital, a specialized biotechnology investor, suggests a vote of confidence in Aclaris Therapeutics. While this filing does not provide new operational or financial performance data, the entry of a significant institutional holder typically warrants a 'hold' recommendation for existing investors, encouraging them to monitor future developments and for potential investors to conduct further due diligence on the company's fundamentals and strategic direction.

Keywords

Aclaris Therapeutics, Deep Track Capital, Deep Track Biotechnology Master Fund, David Kroin, Beneficial Ownership, Schedule 13G, AKTX, Biotechnology Investment, Institutional Ownership